258 related articles for article (PubMed ID: 25525394)
21. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
Tewari KS; Monk BJ
Semin Oncol; 2009 Apr; 36(2):170-80. PubMed ID: 19332251
[TBL] [Abstract][Full Text] [Related]
22. Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo.
Jung HS; Rajasekaran N; Song SY; Kim YD; Hong S; Choi HJ; Kim YS; Choi JS; Choi YL; Shin YK
Int J Mol Sci; 2015 May; 16(6):12243-60. PubMed ID: 26035754
[TBL] [Abstract][Full Text] [Related]
23. Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal.
Kumar L; Gupta S
Oncology; 2016; 91 Suppl 1():8-17. PubMed ID: 27464068
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
26. HPV: Molecular pathways and targets.
Gupta S; Kumar P; Das BC
Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
[TBL] [Abstract][Full Text] [Related]
28. Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer.
Nogueira-Rodrigues A; Melo AC; Werutsky G; Garces AH; Ferreira CG
Curr Cancer Drug Targets; 2016; 16(3):249-60. PubMed ID: 26577537
[TBL] [Abstract][Full Text] [Related]
29. Radiosensitizers in cervical cancer. Cisplatin and beyond.
Candelaria M; Garcia-Arias A; Cetina L; Dueñas-Gonzalez A
Radiat Oncol; 2006 May; 1():15. PubMed ID: 16722549
[TBL] [Abstract][Full Text] [Related]
30. Chemoradiation: A new approach for the treatment of cervical cancer.
Loizzi V; Cormio G; Loverro G; Selvaggi L; Disaia PJ; Cappuccini F
Int J Gynecol Cancer; 2003; 13(5):580-6. PubMed ID: 14675339
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy and concurrent chemoradiation in the treatment of advanced cervical cancer.
Gadducci A; Cosio S; Cionini L; Genazzani AR
Anticancer Res; 2001; 21(5):3525-33. PubMed ID: 11848519
[TBL] [Abstract][Full Text] [Related]
33. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.
Koivusalo R; Krausz E; Ruotsalainen P; Helenius H; Hietanen S
Cancer Res; 2002 Dec; 62(24):7364-71. PubMed ID: 12499281
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
36. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy.
Walzer S; Chouaid C; Lister J; Gultyaev D; Vergnenegre A; de Marinis F; Meng J; de Castro Carpeno J; Crott R; Kleman M; Ngoh C
Expert Rev Anticancer Ther; 2015 Jan; 15(1):121-8. PubMed ID: 25248391
[TBL] [Abstract][Full Text] [Related]
37. Modern management of locally advanced cervical carcinoma.
Dueñas-Gonzalez A; Cetina L; Mariscal I; de la Garza J
Cancer Treat Rev; 2003 Oct; 29(5):389-99. PubMed ID: 12972357
[TBL] [Abstract][Full Text] [Related]
38. Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer.
Lecavalier-Barsoum M; Chaudary N; Han K; Koritzinsky M; Hill R; Milosevic M
Int J Cancer; 2018 Sep; 143(5):1017-1028. PubMed ID: 29417588
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer.
Wagstaff AJ; Keam SJ; McCormack PL
BioDrugs; 2009; 23(3):187-96. PubMed ID: 19627170
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
Cleary JM; Mamon HJ; Szymonifka J; Bueno R; Choi N; Donahue DM; Fidias PM; Gaissert HA; Jaklitsch MT; Kulke MH; Lynch TP; Mentzer SJ; Meyerhardt JA; Swanson RS; Wain J; Fuchs CS; Enzinger PC
BMC Cancer; 2016 Jul; 16():468. PubMed ID: 27412386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
